February, 04 2020 08:30 AM | InvestorBrandNetwor
Post# of 416
(Total Views: 1015)
Posted On: 02/04/2020 11:25:06 AM
Re: whytestocks #402
February, 04 2020 08:30 AM | InvestorBrandNetwork |
Endonovo Therapeutics (OTCQB: ENDV) today announced the reduction of current liabilities and restructuring of the balance sheet through the approved modification of the terms of the Preferred C shares. “Strengthening our balance sheet is a priority we feel is instrumental in our continued and long-term success. This reduction of debt provides us the flexibility to expand our sales and marketing initiatives and to further develop our nationwide reach to hospitals and other medical facilities we have identified as prospective partners without having financial restraints,” Endonovo Therapeutics CEO Alan Collier said in the news release. “Additionally, reducing the debt increases our shareholder equity which is another step towards our goal of attaining Nasdaq listing requirements as we look to uplist. Positioning our company by restructuring and reducing debt will allow us to be in a better position to grow rapidly and capitalize on the increased market growth we are experiencing and will continue to experience.”
To view the full press release, visit http://nnw.fm/VnHV4
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals(R) therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The Company's noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. For more information, visit www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDVD are available in the company’s newsroom at http://nnw.fm/ENDV
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Endonovo Therapeutics (OTCQB: ENDV) today announced the reduction of current liabilities and restructuring of the balance sheet through the approved modification of the terms of the Preferred C shares. “Strengthening our balance sheet is a priority we feel is instrumental in our continued and long-term success. This reduction of debt provides us the flexibility to expand our sales and marketing initiatives and to further develop our nationwide reach to hospitals and other medical facilities we have identified as prospective partners without having financial restraints,” Endonovo Therapeutics CEO Alan Collier said in the news release. “Additionally, reducing the debt increases our shareholder equity which is another step towards our goal of attaining Nasdaq listing requirements as we look to uplist. Positioning our company by restructuring and reducing debt will allow us to be in a better position to grow rapidly and capitalize on the increased market growth we are experiencing and will continue to experience.”
To view the full press release, visit http://nnw.fm/VnHV4
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals(R) therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The Company's noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. For more information, visit www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDVD are available in the company’s newsroom at http://nnw.fm/ENDV
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
(0)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
WORDS TO LIVE BY:
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.